Impact of the Serum Creatinine and Cystatin C Ratio for Prediction of Sarcopenia and Prognosis in Biliary Tract Cancer

Overview

Journal Int J Clin Oncol

Specialty Oncology

Date 2024 Apr 29

PMID 38683456

Authors

Ryosuke Fukushima

Norifumi Harimoto

Takayuki Okuyama

Takaomi Seki

Kouki Hoshino

Kei Hagiwara

Shunsuke Kawai

Norihiro Ishii

Mariko Tsukagoshi

Takamichi Igarashi

Kenichiro Araki

Ken Shirabe

Affiliations

Soon will be listed here.

Abstract

Background: Sarcopenia is a poor prognostic factor in cancer patients. In recent years, there have been reports that serum creatinine and cystatin C (Cr/CysC) ratio is associated with sarcopenia. However, the prognostic value of the Cr/CysC ratio in biliary tract cancer is unclear. We evaluated the impact of the Cr/CysC ratio on sarcopenia and prognosis in biliary tract cancer.

Methods: We retrospectively reviewed the records of 190 patients with biliary tract cancer who had undergone surgical resection from January 2017 to March 2023. Frozen serum samples collected at the time of surgery were used to measure CysC. We calculated the Cr/CysC ratio and investigated the relationship with sarcopenia and the prognostic significance.

Results: We calculated the cutoff value of the Cr/CysC ratio for low skeletal muscle index (SMI) (< 42 cm/m for males and < 38 cm/m for females). The optimal cutoff value of the Cr/CysC ratio was 0.848. The low Cr/CysC ratio group was significantly associated with higher preoperative CRP and lower albumin, lower SMI, lower handgrip strength, and higher intramuscular adipose tissue content. In multivariate analysis, patients with a low Cr/CysC ratio showed poorer overall survival (hazard ratio 2.60, 95% confidence interval 1.07-6.29, p = 0.033), which was significantly worse than in those with a high Cr/CysC ratio.

Conclusions: In patients with biliary tract cancer, the Cr/CysC ratio showed weak correlation with sarcopenic indicators. However, the Cr/CysC ratio could be strong prognostic factor in biliary tract cancer.

References

Ioka T, Shindo Y, Ueno M, Nagano H . Current progress in perioperative chemotherapy for biliary tract cancer. Ann Gastroenterol Surg. 2023; 7(4):565-571. PMC: 10319609. DOI: 10.1002/ags3.12691. View

Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T . Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023; 401(10372):195-203. DOI: 10.1016/S0140-6736(22)02038-4. View

Simonsen C, Heer P, Bjerre E, Suetta C, Hojman P, Pedersen B . Sarcopenia and Postoperative Complication Risk in Gastrointestinal Surgical Oncology: A Meta-analysis. Ann Surg. 2018; 268(1):58-69. DOI: 10.1097/SLA.0000000000002679. View

Harimoto N, Shirabe K, Yamashita Y, Ikegami T, Yoshizumi T, Soejima Y . Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg. 2013; 100(11):1523-30. DOI: 10.1002/bjs.9258. View

Sugimura K, Miyata H, Kanemura T, Takeoka T, Shinnno N, Yamamoto K . Impact of preoperative skeletal muscle mass and physical performance on short-term and long-term postoperative outcomes in patients with esophageal cancer after esophagectomy. Ann Gastroenterol Surg. 2022; 6(5):623-632. PMC: 9444856. DOI: 10.1002/ags3.12560. View

Cruz-Jentoft A, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T . Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2018; 48(1):16-31. PMC: 6322506. DOI: 10.1093/ageing/afy169. View

Chen L, Liu L, Woo J, Assantachai P, Auyeung T, Bahyah K . Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014; 15(2):95-101. DOI: 10.1016/j.jamda.2013.11.025. View

Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A . Cystatin C as a marker of GFR--history, indications, and future research. Clin Biochem. 2004; 38(1):1-8. DOI: 10.1016/j.clinbiochem.2004.09.025. View

Tlemsani C, Durand J, Raynard B, Revel M, Deluche E, Palma M . Relationship between the creatinine/cystatin C ratio and muscle mass measured by CT-scan in cancer patients. Clin Nutr ESPEN. 2022; 51:412-418. DOI: 10.1016/j.clnesp.2022.07.010. View

10.

Yang J, Zhang T, Feng D, Dai X, Lv T, Wang X . A new diagnostic index for sarcopenia and its association with short-term postoperative complications in patients undergoing surgery for colorectal cancer. Colorectal Dis. 2019; 21(5):538-547. DOI: 10.1111/codi.14558. View

11.

Kashani K, Frazee E, Kukralova L, Sarvottam K, Herasevich V, Young P . Evaluating Muscle Mass by Using Markers of Kidney Function: Development of the Sarcopenia Index. Crit Care Med. 2016; 45(1):e23-e29. DOI: 10.1097/CCM.0000000000002013. View

12.

Magister S, Kos J . Cystatins in immune system. J Cancer. 2013; 4(1):45-56. PMC: 3564246. DOI: 10.7150/jca.5044. View

13.

Kos J, Krasovec M, Cimerman N, Nielsen H, Christensen I, Brunner N . Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res. 2000; 6(2):505-11. View

14.

Wu J, Liang Y, Chen R, Xu L, Ou Z, Liang H . Association of plasma cystatin C with all-cause and cause-specific mortality among middle-aged and elderly individuals: a prospective community-based cohort study. Sci Rep. 2022; 12(1):22265. PMC: 9789032. DOI: 10.1038/s41598-022-24722-4. View

15.

Harimoto N, Araki K, Yamanaka T, Hagiwara K, Ishii N, Tsukagoshi M . The ratio of creatinine and cystatin C estimated glomerular filtration rates as a surrogate marker in patients with hepatocellular carcinoma undergoing hepatic resection. J Hepatobiliary Pancreat Sci. 2022; 29(9):964-973. DOI: 10.1002/jhbp.1164. View

16.

Tsukagoshi M, Watanabe A, Araki K, Ishii N, Hagiwara K, Hoshino K . Usefulness of serum creatinine and cystatin C ratio as a screening tool for predicting prognosis in patients with pancreatic cancer. Ann Gastroenterol Surg. 2023; 7(5):784-792. PMC: 10472412. DOI: 10.1002/ags3.12671. View

17.

Dindo D, Demartines N, Clavien P . Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240(2):205-13. PMC: 1360123. DOI: 10.1097/01.sla.0000133083.54934.ae. View

18.

Baumgartner R, Koehler K, Gallagher D, Romero L, Heymsfield S, Ross R . Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998; 147(8):755-63. DOI: 10.1093/oxfordjournals.aje.a009520. View

19.

Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S . Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res. 2016; 46(10):951-63. DOI: 10.1111/hepr.12774. View

20.

Kitajima Y, Hyogo H, Sumida Y, Eguchi Y, Ono N, Kuwashiro T . Severity of non-alcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle. J Gastroenterol Hepatol. 2013; 28(9):1507-14. DOI: 10.1111/jgh.12227. View